“This SBIR grant serves as an independent peer review of our transformative approach to exploit DNA repair defects via DNA modification, which has the potential to one day change the oncology treatment paradigm, particularly for patients with brain cancer,” said Seth Herzon, PhD, Modifi Bio co-founder, and the Milton Harris ’29 PhD Professor of Chemistry in Yale’s Faculty of Arts and Sciences.